Matinas BioPharma (NYSEAMERICAN:MTNB) Releases Earnings Results

Matinas BioPharma (NYSEAMERICAN:MTNB) released its quarterly earnings results on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter, Yahoo Finance reports.

Matinas BioPharma Trading Down 6.5 %

MTNB traded down $0.02 during trading on Friday, hitting $0.27. The company had a trading volume of 1,217,731 shares, compared to its average volume of 2,114,206. The stock has a market capitalization of $58.88 million, a P/E ratio of -2.26 and a beta of 1.52. Matinas BioPharma has a one year low of $0.11 and a one year high of $0.89.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MTNB. Vanguard Group Inc. boosted its holdings in Matinas BioPharma by 6.4% in the 4th quarter. Vanguard Group Inc. now owns 9,317,838 shares of the company’s stock valued at $2,015,000 after purchasing an additional 564,020 shares during the period. Virtu Financial LLC acquired a new stake in shares of Matinas BioPharma during the 4th quarter worth approximately $35,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Matinas BioPharma during the 3rd quarter worth approximately $98,000. Wells Fargo & Company MN boosted its position in shares of Matinas BioPharma by 8,516.7% during the 2nd quarter. Wells Fargo & Company MN now owns 566,550 shares of the company’s stock worth $204,000 after acquiring an additional 559,975 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Matinas BioPharma by 8.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,958,952 shares of the company’s stock worth $705,000 after acquiring an additional 154,094 shares in the last quarter. 11.77% of the stock is currently owned by institutional investors and hedge funds.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.